| pubmed-article:10235111 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10235111 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:10235111 | lifeskim:mentions | umls-concept:C0020097 | lld:lifeskim |
| pubmed-article:10235111 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:10235111 | lifeskim:mentions | umls-concept:C0026549 | lld:lifeskim |
| pubmed-article:10235111 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:10235111 | lifeskim:mentions | umls-concept:C0332197 | lld:lifeskim |
| pubmed-article:10235111 | lifeskim:mentions | umls-concept:C0205420 | lld:lifeskim |
| pubmed-article:10235111 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10235111 | pubmed:dateCreated | 1999-5-28 | lld:pubmed |
| pubmed-article:10235111 | pubmed:abstractText | Human T-cell leukemia virus type I (HTLV-I) infection is emerging as an important complication in HIV infection and AIDS in injecting drug users. HIV-1 and HTLV-I share a common host in CD4+ T lymphocytes. However, the result of HIV-1 infection is the decimation of this cell population, whereas a hallmark of HTLV-I infection is the inappropriate proliferation of infected cells. Combined epidemiologic data suggest that HTLV-I infection is enhanced during concurrent HIV-1/HTLV-I infection; however, there are currently no in vitro studies focusing on the effects of drugs of abuse on retrovirus coinfection. We have found that in an in vitro coinfection system (HIV-1 + HTLV-I), morphine treatment further enhanced the levels of HTLV-I p19. In addition, indicators of in vitro infection by cell-free HIV-1 were reduced by morphine treatment in both single and dual in vitro infection experiments. Interleukin 2 levels in the affected cultures were found to increase with combined HTLV-I infection and morphine treatment. These in vitro results indicate the need to further explore the activity of HTLV-I within opiate-treated cells, as this oncoretrovirus appears to be especially sensitive to morphine-induced alterations to its host cell environment. | lld:pubmed |
| pubmed-article:10235111 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10235111 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10235111 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10235111 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10235111 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10235111 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10235111 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10235111 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10235111 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10235111 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10235111 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10235111 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10235111 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10235111 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:10235111 | pubmed:issn | 1044-5498 | lld:pubmed |
| pubmed-article:10235111 | pubmed:author | pubmed-author:SpecterSS | lld:pubmed |
| pubmed-article:10235111 | pubmed:author | pubmed-author:UgenK EKE | lld:pubmed |
| pubmed-article:10235111 | pubmed:author | pubmed-author:NylandS BSB | lld:pubmed |
| pubmed-article:10235111 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10235111 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:10235111 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10235111 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10235111 | pubmed:pagination | 285-91 | lld:pubmed |
| pubmed-article:10235111 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:10235111 | pubmed:meshHeading | pubmed-meshheading:10235111... | lld:pubmed |
| pubmed-article:10235111 | pubmed:meshHeading | pubmed-meshheading:10235111... | lld:pubmed |
| pubmed-article:10235111 | pubmed:meshHeading | pubmed-meshheading:10235111... | lld:pubmed |
| pubmed-article:10235111 | pubmed:meshHeading | pubmed-meshheading:10235111... | lld:pubmed |
| pubmed-article:10235111 | pubmed:meshHeading | pubmed-meshheading:10235111... | lld:pubmed |
| pubmed-article:10235111 | pubmed:meshHeading | pubmed-meshheading:10235111... | lld:pubmed |
| pubmed-article:10235111 | pubmed:meshHeading | pubmed-meshheading:10235111... | lld:pubmed |
| pubmed-article:10235111 | pubmed:meshHeading | pubmed-meshheading:10235111... | lld:pubmed |
| pubmed-article:10235111 | pubmed:meshHeading | pubmed-meshheading:10235111... | lld:pubmed |
| pubmed-article:10235111 | pubmed:meshHeading | pubmed-meshheading:10235111... | lld:pubmed |
| pubmed-article:10235111 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10235111 | pubmed:articleTitle | Morphine effects on HTLV-I infection in the presence or absence of concurrent HIV-1 infection. | lld:pubmed |
| pubmed-article:10235111 | pubmed:affiliation | Department of Medical Microbiology and Immunology, University of South Florida College of Medicine, Tampa 33612, USA. | lld:pubmed |
| pubmed-article:10235111 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10235111 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
